Giannis Mountzios Shares Study on Molecular Determinants of Sotorasib Efficacy in KRAS G12C Mutant NSCLC
Giannis Mountzios, Director of the 4th Oncology Department and Clinical Trials Unit at Henry Dunant Hospital Center, shared a post on LinkedIn:
“Patients with NSCLC harboring the KRAS G12C mutation comprise a distinct group of lung cancer, usually being smokers with adenocarcinoma histology.
We know from clinical practice that not all patients respond the same to selective KRAS G12C inhibitors such as sotorasib. This recent publication in Nature Medicine sheds light into the molecular landscape of KRAS G12C mutant NSCLC identifying low expression of TTF1 and KEAP1 co-mutations/NRF2 activation as major determinants of sotorasib anti-tumor efficacy and adverse prognostic features.
I was really happy to contribute to this global effort and I learned so many things from each single patient I included in this analysis. I feel grateful to leading author Ferdinandos Skoulidis for spearheading this global effort and to Amgen Oncology science team for their amazing support and collaboration.
Those findings establish a framework for patient stratification and selection for treatment intensification with rationally applied therapeutic combinations.”
Title: Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer
Title: Ferdinandos Skoulidis, Bob T. Li, Adrianus Johannes de Langen, David S. Hong, Herve Lena, Juergen Wolf, Grace K. Dy, Alessandra Curioni Fontecedro, Pascale Tomasini, Vamsidhar Velcheti, Anthonie J. van der Wekken, Christophe Dooms, Luis Paz-Ares Rodriguez, Giannis Mountzios, Adrian Sacher, Ernest Nadal, Sebastien Couraud, Sang-We Kim, Kenneth O’Byrne, Danilo Rocco, Ryo Toyozawa, Izabela Chmielewska, Colin R. Lindsay, Antreas Hindoyan, Lata Mukundan, Tomasz Wilmanski, Abraham Anderson, Christine Ardito-Abraham, Amrita Pati, Anita Reddy, Bhakti Mehta, Martin Schuler
You can read the Full Article on Nature Medicine.
More posts featuring Giannis Mountzios.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023